NCT03377387
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: 
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastasis – see trial for details
https://ClinicalTrials.gov/show/NCT03377387